Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Soligenix (NASDAQ:SNGX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Profitability
This table compares Cartesian Therapeutics and Soligenix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
| Soligenix | N/A | -180.25% | -107.46% |
Earnings & Valuation
This table compares Cartesian Therapeutics and Soligenix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cartesian Therapeutics | $2.80 million | 85.02 | -$130.30 million | ($5.94) | -1.32 |
| Soligenix | $120,000.00 | 47.56 | -$11.08 million | ($0.98) | -0.39 |
Soligenix has lower revenue, but higher earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Cartesian Therapeutics and Soligenix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Soligenix | 1 | 0 | 0 | 0 | 1.00 |
Cartesian Therapeutics currently has a consensus target price of $32.60, suggesting a potential upside of 314.23%. Given Cartesian Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than Soligenix.
Insider and Institutional Ownership
87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 1.9% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Cartesian Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.
Summary
Cartesian Therapeutics beats Soligenix on 9 of the 14 factors compared between the two stocks.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
About Soligenix
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
